Tag Archives: NASDAQ:RVNC

Revance Therapeutics (RVNC) Receives a Buy from Cantor Fitzgerald

In a report released today, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Revance Therapeutics (NASDAQ: RVNC), with a price target of $50. The company’s shares opened today at $23.01, close to its 52-week low of $21.45. Chen

Cantor Fitzgerald Thinks Revance Therapeutics’ Stock is Going to Recover

Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Revance Therapeutics (NASDAQ: RVNC) today and set a price target of $50. The company’s shares opened today at $23.14, close to its 52-week low of $22.25. Chen noted: “We expect

Cantor Fitzgerald Remains a Buy on Revance Therapeutics (RVNC)

Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Revance Therapeutics (NASDAQ: RVNC) today and set a price target of $50. The company’s shares opened today at $25.68. Chen observed: “We expect upward earnings revisions to levels not reflected

Cantor Fitzgerald Gives a Buy Rating to Revance Therapeutics

In a report released today, Louise Chen from Cantor Fitzgerald assigned a Buy rating to Revance Therapeutics (NASDAQ: RVNC), with a price target of $50. The company’s shares closed on Friday at $31.15. Chen commented: “We expect upward earnings revisions

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Revance Therapeutics (NASDAQ: RVNC) and BioMarin (NASDAQ: BMRN)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Revance Therapeutics (NASDAQ: RVNC) and BioMarin (NASDAQ: BMRN). Revance Therapeutics (NASDAQ: RVNC) In a report released today, Rohit Vanjani from Guggenheim maintained a

Cantor Fitzgerald Reaffirms Their Buy Rating on Revance Therapeutics

Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Revance Therapeutics (NASDAQ: RVNC) today and set a price target of $50. The company’s shares opened today at $29.85. Chen commented: “Today, RVNC announced four new senior roles for its